Posted On: 11/08/2014 3:16:05 AM
Post# of 30067
For the next 12 months, the Company intends to focus primarily on the commercialization of LymPro, the further clinical development of
Eltoprazine, and the preclinical development of MANF.
Exploration of the Company’s PhenoGuard platform for neurotrophic factor discovery and discovery and evaluation of external drug
candidates for potential in-licensure or acquisition.
Eltoprazine, and the preclinical development of MANF.
Exploration of the Company’s PhenoGuard platform for neurotrophic factor discovery and discovery and evaluation of external drug
candidates for potential in-licensure or acquisition.
(0)
(0)
